SeaStar Medical Holding Corp(ICU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:09 PM ET (Korea 10/31 07:09)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.93 | Insider Own | 3.1% | Shs Outstand | 4.4M | Perf Week | -7.05% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 42.9% | Insider Trans | 0.55% | Shs Float | 4.3M | Perf Month | -40.27% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.95 | Inst Own | 3.86% | Short Float | 4.35% | Perf Quarter | -29.89% |
| Income | -0.01B | P/S | 5.77 | EPS this Y | 37.54% | Inst Trans | 1.15% | Short Ratio | 1.51 | Perf Half Y | -48.74% |
| Sales | 0.00B | P/B | 2.22 | EPS next 5Y | 49.38% | ROA | -160.02% | Short Interest | 0.19M | Perf YTD | -6.67% |
| Book/sh | 1.01 | P/C | 1.42 | EPS past 3/5Y | 74.91% -125.73% | ROE | -356.87% | 52W High | -62.67% ($6.00) | Perf Year | -59.65% |
| Cash/sh | 1.58 | P/FCF | - | Sales past 3/5Y | - | ROIC | -317.2% | 52W Low | 8.21% ($2.07) | Perf 3Y | -99.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 83.96% | Gross Margin | 92.64% | Volatility(W/M) | 6.46% 12.63% | Perf 5Y | -99.91% |
| Dividend TTM | - | EV/Sales | 1.78 | Sales Y/Y TTM | 123.63% | Oper. Margin | -816.64% | ATR (14) | 0.32 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.87 | EPS Q/Q | 48.32% | Profit Margin | -795.5% | RSI (14) | 35.38 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.89 | Sales Q/Q | 81.95% | SMA20 | -26.05% ($3.03) | Beta | -1.11 | Target Price | $12 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/12 | SMA50 | -29.89% ($3.19) | Rel Volume | 0.66 | Prev Close | $2.31 |
| Employees | 17 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 6.19% 26.41% | SMA200 | -32.67% ($3.33) | Avg Volume(3M) | 0.12M | Price | $2.24 |
| IPO | 2021/3/18 | Option/Short | No/Yes | Trades | 346 | Volume | 81,711 | Change | -3.03% |
🩺 SeaStar Medical () is a commercial-stage healthcare company that develops and sells a Selective Cytopheretic Device (SCD) aimed at treating organ failure in critically ill patients. Its flagship product, QUELIMMUNE™, is the only therapeutic device to have received FDA approval for pediatric sepsis patients with acute kidney injury (AKI), and the company is working to expand its indications to include adult AKI and systemic inflammatory response following cardiac surgery.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
ICU has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $577. Peers typically go for $1,010.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
DBC Invesco DB Commodity Index Tracking Fund 1.9B 
CERY SPDR Enhanced Roll Yield Commodity 1.3B 
DBA Invesco DB Agriculture Fund 1.1B 
MOO VanEck Agribusiness ETF 1.1B 
NANR State Street SPDR S&P North American Natural Resources ETF 840M It ranks #508 of 597 in the industry
Based on market cap of $10M.
CALC#505 CalciMedica Inc $10M PER - 
TPST#506 Tempest Therapeutics Inc $10M PER - 
BLRX#506 Bioline Rx Ltd ADR $10M PER - ICU#508 SeaStar Medical Holding Corp $10M PER - 
LTRN#508 Lantern Pharma Inc $10M PER - 
FAQ
What kind of company is ICU?
ICU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ICU?
The market cap of ICU is approximately $10M, ranking 5,438 within its sector.
What is the 52-week high and low for ICU?
ICU has recorded a 52-week high of $6.00 and a low of $2.07.
